Placental growth factor as a new marker for predicting abnormal glucose challenge test results

Abstract Background: To differentiate placental growth factor (PlGF) levels in pregnancies with normal and abnormal glucose challenge test (GCT) results. Methods: A total of 94 pregnant women underwent a 50 -g GCT as part of our routine antenatal screening protocol from September 2011 to January 201...

Full description

Saved in:
Bibliographic Details
Published in:Gynecological endocrinology 2013-10, Vol.29 (10), p.909-911
Main Authors: Cengiz, Hüseyin, Kaya, Cihan, Ekin, Murat, Yesil, Ali, Da deviren, Hediye
Format: Article
Language:English
Subjects:
Adult
Biomarkers - blood
Case-Control Studies
Diabetes
Diabetes, Gestational - blood
Diabetes, Gestational - diagnosis
Female
Glucose Tolerance Test
Humans
insulin
Placenta Growth Factor
Pregnancy
Pregnancy Proteins - blood
Pregnancy Proteins - physiology
Prognosis
Retrospective Studies
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background: To differentiate placental growth factor (PlGF) levels in pregnancies with normal and abnormal glucose challenge test (GCT) results. Methods: A total of 94 pregnant women underwent a 50 -g GCT as part of our routine antenatal screening protocol from September 2011 to January 2012. The patients were divided into three groups: (i) normal GCT, (ii) abnormal GCT and (iii) gestational diabetes mellitus (GDM) based on the screening results for gestational diabetes. The main outcome measure of the study was the relationship between PlGF and GCT results in non-diabetic pregnancies. The Kolmogorov-Smirnov test was used to check the normality of the variables' distributions. The Kruskal-Wallis and analysis of variance tests (Tukey's test) were used to analyze the qualitative parameters. Results: There were 53 (56.4%), 22 (23.4%) and 19 (20.2%) patients in the normal GCT, abnormal GCT and GDM groups, respectively. The PlGF level in the abnormal GCT group was 518 ± 307.6 pg/mL, which was the highest level in the study population, and there was a statistically significant difference compared with the other groups (p = 0.006). There were no statistically significant differences with respect to fetal birth weight among the three groups in our study. Conclusion: PlGF can be used as a laboratory marker to predict which patients will have abnormal GCT results.
ISSN:0951-3590
1473-0766
DOI:10.3109/09513590.2013.813477